Focal adhesion kinase (FAK) is a nonreceptor tyrosine kinase involved in development and human disease, including cancer. It is currently thought that the four-point one, ezrin, radixin, moesin (FERM)-kinase domain linker, which contains autophosphorylation site tyrosine (Y) 397, is not required for in vivo FAK function until late midgestation. Here, we directly tested this hypothesis by generating mice with FAK Y397-to-phenylalanine (F) mutations in the germline. We found that Y397F embryos exhibited reduced mesodermal fibronectin (FN) and osteopontin expression and died during mesoderm development akin to FAK kinase-dead mice. We identified myosin-1E (MYO1E), an actin-dependent molecular motor, to interact directly with the FAK FERM-kinase linker and induce FAK kinase activity and Y397 phosphorylation. Active FAK in turn accumulated in the nucleus where it led to the expression of osteopontin and other FN-type matrix in both mouse embryonic fibroblasts and human melanoma. Our data support a model in which FAK Y397 autophosphorylation is required for FAK function in vivo and is positively regulated by MYO1E.
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focal adhesion | myosin | fibronectin | melanoma | cancer F ocal adhesion kinase (FAK) is a nonreceptor tyrosine kinase involved in many biological processes, ranging from mesoderm development to cancer cell metastasis (1) . FAK localizes to focal adhesions (2) , where it becomes part of a multiprotein complex that links the extracellular matrix (ECM) to the intracellular actin cytoskeleton. FAK is also found in the nucleus, where it is believed to relay information from the cell cortex (3) and induce transcriptional changes (4) . The domain architecture of FAK comprises a four-point one, ezrin, radixin, moesin (FERM) domain that is separated from a C-terminal catalytic kinase domain by the FERM-kinase linker. FAK kinase-dead (5) embryos die with mesodermal defects during late gastrulation. In contrast, mice with conditional FAK deletions in the epidermis (6) or breast epithelium (7) show resistance to carcinogenesis.
Although FAK has important biological functions, the mechanisms regulating its activity are incompletely understood. For example, it is unclear whether the FERM-kinase linker that contains autophosphorylation site tyrosine (Y) 397 is required for FAK activity in vivo (8) . In its closed, inactive conformation, the FAK kinase domain is autoinhibited through interaction with the N-terminal FERM domain. Y397 is nonphosphorylated (9) . Upon activation by tethering (10) or other stimuli that induce conformational change (11) , the linker region is exposed and Y397 becomes autophosphorylated, leading to the recruitment of the protooncogene SRC. FAK and SRC then form a transient complex, which stabilizes FAK in its active conformation and induces changes in cell shape and focal adhesion turnover in vitro (12) . However, mice with a 19-aa deletion in the FAK linker that includes Y397 develop normally until midgestation (8) .
Here, we have mechanistically discerned the contributions of Y397 to FAK function in vivo. Moreover, we screened for proteins that directly interact with the FAK linker, activate FAK kinase activity, and induce Y397 autophosphorylation.
Results

FAK Y397F Embryos Die Early During Mesoderm Development.
To determine the contribution of the FAK FERM-kinase domain linker to FAK function in vivo, Y397 was substituted with the nonphosphorylatable amino acid phenylalanine (F) in the germline of mice (Fig. S1 ). Although mice heterozygous for the Y397F mutation displayed no apparent phenotype, their intercross failed to produce live homozygous offspring (Tables S1 and S2 ). Timed matings revealed that the development of homozygous FAK Y397F embryos stalled at embryonic day (E) 9.5 with a phenotype characterized by hemorrhage, an unorganized somite structure,
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The phenotype of FAK Y397F resembled the phenotype of fibronectin (FN)-deficient embryos (13) . Because FAK has been shown to mediate FN expression (14) and an FN-rich matrix is critical for angiogenesis (13), we tested whether the vascular phenotype of FAK Y397F embryos was accompanied by an abnormal FN-type matrix. We found that FN protein was substantially reduced in cryosections of E9.5 FAK Y397F embryos (Fig. 1E) , whereas laminin and collagen expression was unchanged (Fig. 1E) . Using quantitative PCR on whole-embryo-derived RNA at E9.5 to screen for other ECM affected by FAK Y397F, we found a strong mutation-induced reduction in the expression of osteopontin (SPP1; Fig. 1F ), an Arg-Gly-Asp (RGD) tripeptide-containing ligand of FN-binding integrins involved in angiogenesis and bone formation (15) . Together, our data showed that the FAK FERMkinase linker is required for normal mesoderm development and the expression of FN-type ECM.
FAK Proline-Rich Region 1 Binds Myosin 1E Through Arginine 358 and Prolines 371 and 374. Next, we wanted to define the protein complex that forms at the FERM-kinase linker to promote FAK function through Y397 and induce FN-type ECM. To identify FAK linker interacting protein(s), we used stable isotope labeling by amino acids in cell culture (SILAC), followed by pull-down experiments with synthesized FAK linker peptide (amino acids 358-409; Fig.  2A ) or scrambled peptide (to identify nonspecific interactors). Protein identification and quantification was by mass spectrometrybased proteomics. Among proteins that bound specifically to phospho-Y397 FAK peptide were SRC, actinin-4 (ACTN4), and myosin-1E (MYO1E) (Fig. 2B ). Of these proteins, only MYO1E bound to nonphosphorylated FAK peptide versus scrambled peptide (Fig. S2A) and equally well to phospho-Y397 and nonphosphorylated FAK peptides (Fig. S2B) . To test whether the binding of SRC, MYO1E, and ACTN4 to FAK peptides was direct or indirect, we produced GST-tagged recombinant protein and pursued in vitro binding studies. We found that recombinant GSTtagged ACTN4 did not bind FAK peptides directly. In agreement with the proteomics data, full-length SRC-GST precipitated with phospho-Y397, but not nonphosphorylated FAK peptide (Fig. 2C ) or FAK Y397F peptide (Fig. 2D) .
MYO1E, the third identified FAK interacting protein, is one of only two class I myosins that contain an SH3 domain (16) . MYO1E has previously been shown to localize to integrin adhesions (17) and to colocalize with paxillin in cancer cell invadosomes (16) , where it promotes receptor-mediated endocytosis (18) . In WM858 melanoma cells, a BRAF V600E cell line that expresses high amounts of FN and SPP1 (19) , MYO1E organized into rosette-like structures surrounding a paxillin core (Fig. 2E ). FAK and MYO1E colocalized in a confocal plane at the interface of the core and rosette (Fig. 2E ). Endogenous FAK from adherent or suspended cells coimmunoprecipitated with full-length MYO1E irrespective of FAK Y397 phosphorylation ( Fig. 2F ) and was pulled down by recombinant GST-tagged wild-type MYO1E SH3, but not by mutated MYO1E SH3, harboring a tryptophan (W)-to-lysine (K) mutation at position 1088 (W1088K; Fig. 2G ). The folding of this mutant was confirmed by circular dichroism and NMR (Fig. S3) . Moreover, recombinant MYO1E SH3 bound directly to the synthesized and bead-immobilized FAK linker (amino acids 358-409; Fig. 2H ). This interaction was almost completely disrupted by the addition of RALPSIPK (Fig. 2H) , an octapeptide uniquely found in FAK proline-rich region 1 (PRR1) and sufficient to bind MYO1E SH3 (Fig. S4) . No effects on MYO1E SH3 binding could be observed upon addition of the scrambled PLAIRKSP peptide (Fig.  2H ). Because these findings indicated that MYO1E binds PRR1 of FAK, we next synthesized peptides with point mutations in critical PRR1 residues: mutations in arginine (R) 368, which is thought to form a salt bridge with E1070 of MYO1E, and in prolines (P) 371/ 374, which likely adopt a polyproline type II helical structure that interacts with the MYO1E SH3 domain. Results showed that the R368A mutation, as well as the PP371/374AA (PAPA) mutation, inhibited FAK binding to wild-type MYO1E SH3 (Fig. 2I ).
Structural Analysis of the MYO1E SH3-FAK PRRI Interaction. We next used NMR spectroscopy and isothermal titration calorimetry (ITC) to determine the dissociation constant (K d ) of the MYO1E SH3-FAK PRR1 interaction. Recombinant 15 N-labeled apo MYO1E SH3 showed a very high-quality NMR spectrum with well-dispersed peaks indicating a folded and monomeric protein. Upon addition of RALPSIPK peptide, peaks affected by the interaction shifted due to changes in the environment of affected amino acids. The chemical shift perturbations (CSPs) of four peaks observed during titration were used to determine the K d of the interaction at 51 μM (Fig. 3A) . The K d determined by NMR was then used to define the setup of two independent ITC experiments, which yielded a K d of 22 ± 1 μM (Fig. 3B) , confirming the order of magnitude of the affinity of this interaction. These affinities were similar to the affinities of the SRC SH3-FAK PRR1 interaction with reported K d s between 32 and 63 μM depending on method (20) . To investigate the mode of interaction between FAK PRR1 and MYO1E SH3, we assigned the peaks in the (Fig. 3C) . Although CSPs are spread throughout the domain, the part of the protein most affected by the binding clusters to one region, exemplified by the strong shifts in residues W1089, F1100, N1102, and N1103. Additionally, we assigned the peaks corresponding to the side chain imines of W1088 and W1089 (Fig. S3B) , and found that the side chain of the crucial residue, W1088, displays a very large CSP, even though the perturbation of the backbone amide is only moderate. This binding surface is in accordance with the canonical binding surface of proline-rich peptides on SH3 domains, located in-between the RT loop and the n-Src loop on the C-terminal helix. Superposition of the MYO1E SH3 domain with the structure of the SRC SH3 domain in complex with a class 1 peptide confirms this mode of interaction. This model underlines the importance of peptide residues R368, P371, and P374 for the interactions that were observed in pull-down experiments.
Myosin 1E Induces FAK Kinase Activity and Downstream SPP1 Expression in Fibroblasts. To test whether MYO1E SH3 induces FAK kinase activity, we performed in vitro FAK kinase reactions in the presence of 1:2 titrated MYO1E SH3. When MYO1E SH3 was incubated with full-length FAK, kinase activity increased several fold (Fig. 4A ). An increase in kinase activity was not observed when MYO1E SH3 was incubated with FAK kinase domain (amino acids 393-698) devoid of FAK PRR1 (Fig. 4A) . To test whether FAK PRR1 induces FAK Y397 autophosphorylation in cells, we reconstituted FAK-null fibroblasts with PRR1-mutated FAK. Immunoblots revealed a significant reduction in phospho-Y397 FAK with the PAPA or R368A mutation. When separating nuclear from cytoplasmic fractions, R368A or PAPA-induced reductions in phospho-Y397 FAK were in the nuclear compartment (Fig. 4B) . Conversely, reexpression of MYO1E in MYO1E-null fibroblasts increased FAK Y397 phosphorylation (Fig. 4C) . Specifically, MYO1E promoted the nuclear accumulation of total and phospho-Y397 FAK (Fig. 4D) .
Because phospho-Y397 FAK was abundant in the nucleus of MYO1E-reconstituted cells, we next tested whether FAK Y397 promoted the expression of FN-type ECM as observed in FAK Y397F embryos. Total sequencing of RNA from FAK-null or FAK-reconstituted wild-type or Y397F fibroblasts yielded ∼41,000 sequenced genes. Two hundred seventy-two genes were in a union of genes differentially expressed in FAK-null versus wild-type fibroblasts and FAK wild-type versus Y397F fibroblasts (Dataset S1). One hundred one genes had lower expression in FAK-null and Y397F cells compared with FAK wild-type cells, and thus depended on Y397 for their up-regulation; functional association analysis of these 101 genes by STRING (stringdb.org) revealed an FN-centered cluster (Fig. 4E) . One of the most highly FAK-induced genes was SPP1 (Fig. 4F) . In line with these data, reexpression of MYO1E in MYO1E-null fibroblasts induced SPP1/FN mRNA (Fig. 4G) , whereas SPP1/FN mRNA was reduced in the presence of FAK PAPA compared with wildtype FAK (Fig. 4H) . Consistent with the role of FN and SPP1 in promoting cell proliferation and invasion, FAK Y397F fibroblasts grew less confluently and invaded less well into Matrigel than wild-type controls (Fig. 4I) . Likewise, FAK PAPA fibroblasts grew less confluently than wild-type controls (Fig. 4J) . Conversely, MYO1E-reconstituted fibroblasts grew more confluently and invaded faster into Matrigel than MYO1E-null controls (Fig. 4K ).
MYO1E/FAK Induces SPP1 Promoter Activity and Proliferation in
Melanoma Cells. FAK and MYO1E could be visualized in the cytoplasm and nucleus of WM858 melanoma cells by postembedding immunogold electron microscopy (Fig. 5A ). In these SPP1/ FN high-expressing cancer cells (19) , the nuclear-to-cytoplasmic phospho-Y397 FAK ratio was high (Fig. 5B ) compared with wildtype FAK-cherry reconstituted mouse embryonic fibroblasts (Fig.  5C ). High levels of nuclear phospho-Y397 FAK were also observed in patient-derived melanoma xenograft cell lines M12 and M15 and patient-derived in-transit cutaneous melanoma metastases (Fig.  S5) . To test whether Y397 phosphorylation promotes FAK nuclear accumulation, WM858 cells were treated with the FAK kinase inhibitor PF-562271, which prevented FAK Y397 phosphorylation. We found that nuclear FAK was reduced in the presence of PF-562271, as was nuclear SRC (Fig. 5B) . Moreover, in WM858 cells that expressed wild-type or Y397F FAK-cherry, nuclear Y397F was reduced compared with wild type (Fig. 5F ), indicating that the Y397F mutation interferes with nuclear FAK accumulation. Likewise, total and phospho-Y397 nuclear FAK was reduced in cells with reduced MYO1E mRNA due to effective MYO1E shRNA derived from RNAi Consortium (TRC) clones 152421 and 152890 versus ineffective shRNA from clone 151296 and nontargeting control shRNA (Fig. 5G) .
To investigate whether nuclear FAK promotes FN-type ECM expression in WM858 cells, we performed six chromatin immunoprecipitation with massively parallel DNA sequencing (ChIP-seq) experiments. These experiments revealed that FAK associates with the consensus binding sequence GCGC[AC]TGCGC. This binding sequence is highly similar to the optimal binding site for nuclear respiratory factor 1 (NRF1), (T/C)GCGCA(C/T)GCGC(A/G) (Fig. S6) , which coregulates promoter activity of SPP1 family genes (21) . To test whether FAK drives SPP1 promoter activity, we tagged the endogenous SPP1 promoter in WM858 cells with a dual-luciferase reporter (Dual-Glo cells). Firefly luciferase was introduced to assay SPP1 promoter activity, and Renilla luciferase was coupled to the CMV promoter as a loading control. As expected, the SPP1 promoter was activated by vitamin D, because it was shown to harbor vitamin D response elements (22) (Fig. 5H) . Retinoic acid receptor agonists, reported previously to induce SPP1 (23) , also induced SPP1 promoter activity (Fig. 5I) , as did stable overexpression of FAK wild type-cherry and MYO1E-GFP (Fig. 5J) . We then performed an unbiased screen of pharmaceutically active compounds to identify compounds that inhibit SPP1 promoter activity. We found that the structurally related FAK kinase inhibitors PF-431396 and PF-562271 were among a handful of drugs that strongly inhibited SPP1 promoter activity (Fig. 5K) . Another structurally unrelated FAK inhibitor, PF-573228, was less potent. Interestingly, neither SRC kinase inhibitors nor small-molecule inhibitors of mitogen-activated or rapidly accelerated fibrosarcoma kinases (RAFs) inhibited SPP1 promoter activity (Fig. S7) . SPP1 promotes melanoma cell proliferation and tumor growth (24) . Exposure of WM858 or M12 cells to PF-562271 inhibited proliferation, as determined by automated counting of fluorescently labeled nuclei with a half-maximal effective concentration of 0.3 ± 0.1 μM. Likewise, isopropyl β-D-1-thiogalactopyranoside-inducible shRNA targeting FAK in WM858 cells inhibited proliferation (Fig. 5L) . When FAK-depleted cells were transiently reconstituted with either wild-type or PAPA mutant murine FAK, wild-type cells proliferated faster (Fig. 5M) . Moreover, knockdown of MYO1E using effective shRNA TRCN152890, but not ineffective shRNA TRCN151296 or nontargeting control shRNA, inhibited proliferation of WM858 cells (Fig. 5N) . Together, these data are consistent with a model where upon MYO1E interaction with FAK in melanoma cells, FAK becomes activated and accumulates in the nucleus to induce SPP1 promoter activity and proliferation. In line with this model, nuclear phospho-Y397 FAK-positive cutaneous melanoma expressed higher levels of SPP1 than nuclear phospho-Y397 FAK-negative precursor tissue (Fig. S5) . Moreover, in cutaneous melanoma, mitotic rate is an independent adverse predictor of survival (25) , indicating a possible role for MYO1E/FAK-driven cancer cell proliferation in prognostically important processes.
Discussion
In the present study, we found that FAK function in vivo critically depends on the release of FAK kinase autoinhibition and dependent Y397 autophosphorylation. Moreover, FAK kinase activity is induced by a direct interaction of MYO1E and FAK. Once the FAK kinase domain is released from autoinhibition, SRC binds to phospho-Y397, thereby stabilizing the release of autoinhibition (9) . Full catalytic activity in turn leads to nuclear accumulation of FAK, and transcription of FAK target genes such as SPP1 and FN.
We identified MYO1E as a FAK PRR1 interactor. In contrast to SRC, MYO1E binds the FERM-kinase linker in the absence of phospho-Y397. MYO1E SH3-mediated autoinhibition of MYO1E motor function (26) may be released by MYO1E binding to FAK. MYO1E binding to FAK then tethers FAK to actin, which may promote endocytosis (18) and could explain why FAK function is tightly linked to actomyosin dynamics and integrin endocytosis (10, 27) . Upon FAK Y397 autophosphorylation, SRC binds FAK through SH2 domain interaction, which, in turn, releases SRC SH3 to interact with FAK PRR1, thereby possibly replacing MYO1E. Simultaneous binding of SRC SH2 and SH3 to FAK linker profoundly increases affinity versus SH2 binding alone (20) . In the absence of phospho-Y397, the affinity of MYO1E SH3 for FAK PRR1 octapeptide RALPSIPK is only marginally higher than the affinity of SRC SH3. However, in peptide pull-down experiments using full-length nonphosphorylated FAK linker peptide, SRC is not easily precipitated (via its SH3 domain) in the absence of Y397 phosphorylation. This finding suggests that the affinity of fulllength SRC for FAK linker is lower than the affinity of recombinant SRC SH3 (28) , specifically in the absence of SH2 binding to phospho-Y397, or that MYO1E and FAK interact at additional sites outside of the RALPSIPK sequence either directly or indirectly that have yet to be determined.
The ability of MYO1E/FAK to influence matrix composition is consistent with in vivo MYO1E/FAK mutant phenotypes. Normal epidermis, which is avascular and does not depend on FN receptors and ligands, is unaffected by changes in MYO1E or FAK function (6, 29) . On the other hand, complex mesenchymal processes such as neovascularization require the induction of an FN-based ECM (30) and are affected by FAK (31) or MYO1E loss of function (29) . Cancer cells produce an FN-rich fibrotic matrix to facilitate metastasis, and both FAK (4, 7) and MYO1E (32) promote carcinogenesis in murine cancer models. In addition, MYO1E protects kidney podocytes from mechanical stressinduced injury, as does SPP1, which may be induced by FAK (33, 34) . Moreover, keloid formation (i.e., a wound-healing reaction with excessive scar formation) has been associated with MYO1E (35) and FAK function (36) . MYO1E/FAK-induced SPP1 may play a role in keloid formation because SPP1 is known to drive tissue fibrosis (37) . Melanoma expresses high levels of SPP1 and other FN-type ECM, which, in turn, promotes metastasis (19, 38) . Consistent with a role of nuclear phospho-Y397 FAK in driving SPP1 expression, we found high levels of phospho-Y397 FAK in the nucleus of patient-derived melanoma tissues and cell lines. In mouse embryonic fibroblasts, phospho-Y397 FAK was abundant in the cytoplasm. Other authors have reported a predominantly cytoplasmic localization of phospho-Y397 FAK [e.g., in human umbilical vein endothelial cells (3)]. The molecular basis for this discrepancy is not well understood but may involve MYO1E. Future research must address the mechanisms that drive the nuclear shuttling of FAK to provide additional insight into medically relevant processes that rely on ECM remodeling. SILAC-Based Peptide Pull-Downs. SILAC labeling of WM858 melanoma cells was by 13 C 6 L-lysine and 13 C 6 , 15 N 4 L-arginine. Proteins were precipitated as described previously (39) .
Materials and Methods
NMR Spectroscopy. NMR spectra were recorded at 25°C on a Bruker AVIII-600 spectrometer with a room temperature probe head. Details on NMR and the expression and purification of recombinant proteins are provided in SI Materials and Methods.
ITC. Binding constants were determined using a NanoITC instrument (TA Instruments). Details are provided in SI Materials and Methods.
Nuclear Extractions. Separation of the nuclear fraction from the cytoplasmic fraction of cells was achieved using a kit (40010; Active Motif) and following the manufacturer's instructions. Details on coimmunoprecipitation, GST pull-downs, and microfluidic Western blots by ProteinSimple are provided in SI Materials and Methods.
Statistics. Statistical analysis was performed using GraphPad Prism software (version 6.05; GraphPad Software). Statistical significance was determined as indicated.
